These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 802071)

  • 21. [The relation between anti-hypertensive action and plasmatic concentration of pindolol. Preliminary study].
    Weiss Y; Loria Y; Lavene D; Georges D; Safar M; Milliez P
    Nouv Presse Med; 1977 Mar; 6(11):927-30. PubMed ID: 322092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Australian National Blood Pressure Study.
    Abernethy JD
    Med J Aust; 1974 May; 1(21):821-4. PubMed ID: 4605365
    [No Abstract]   [Full Text] [Related]  

  • 23. [Value of hydralazine-beta blockader association in hypertension of pregnancy].
    Monnier JC; Honore P; Lanciaux B; Boulogne M
    Lille Med; 1978; 23(9):660-6. PubMed ID: 32453
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of ketanserin and pindolol in hypertension.
    Gordin A; Saraste K; Turanlahti M; Sundberg S
    J Hypertens Suppl; 1986 Apr; 4(1):S61-2. PubMed ID: 2939214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of labetalol, hydrallazine, and propranolol in the therapy of moderate hypertension.
    West MJ; Wing LM; Mulligan J; Walkley J; Grygiel JJ; Graham JR; Chalmers JP
    Med J Aust; 1980 Mar; 1(5):224-5. PubMed ID: 6990215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double blind drug trial of LB-46 (visken) in angina pectoris.
    Sainani GS; Mukherjee AK
    Indian Heart J; 1972 Jun; 24():Suppl 1:192-6. PubMed ID: 4581427
    [No Abstract]   [Full Text] [Related]  

  • 27. [Potassium metabolism in combined administration of pindolol and clopamide in long-term treatment of hypertension (author's transl)].
    Faupel RP; Gotzen R
    Dtsch Med Wochenschr; 1978 Oct; 103(41):1602-5. PubMed ID: 100301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive action of drug combination: Timolol, hydralazine, hydrochlorothiazide and triamterene.
    Pörsti P; Jalonen K; Ryysy L; Toivonen T; Viherkoski M
    Ann Clin Res; 1981 Feb; 13(1):6-10. PubMed ID: 7018363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)].
    Persson I; Ulrich J
    Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952
    [No Abstract]   [Full Text] [Related]  

  • 30. [Experience with the combination of beta receptor blockader and hydralazine in the treatment of hypertension].
    Jensen HE; Rasmussen K
    Ugeskr Laeger; 1976 Mar; 138(14):860-3. PubMed ID: 772901
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of the combination of Pindolol and clopamide in systemic arterial hypertension. A multicenter study].
    Zilenovski AM; Freire CA
    Arq Bras Cardiol; 1981 Sep; 37(3):219-24. PubMed ID: 7052028
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of essential hypertension with pindolol and clopamide: problems arising from a combined beta blocker and diuretic therapy.
    Rosenfeld JB; Traub YM; Cohen L
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):786-97. PubMed ID: 4217245
    [No Abstract]   [Full Text] [Related]  

  • 33. Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris.
    Zetterquist S; Furberg C; Ringqvist I; Söderholm B
    Curr Ther Res Clin Exp; 1975 Feb; 17(2):139-48. PubMed ID: 803427
    [No Abstract]   [Full Text] [Related]  

  • 34. [Multicenter study of atenolol, combined with hydralazine and bendroflumethiazide in the treatment of essential, mild, and severe, arterial hypertension].
    Ferreira IJ; Escosa L; Casasnovas JA; Barrios SJ; Marcos JM; Pardell H; Navarro A; de la Fuente V
    An Med Interna; 1989 Mar; 6(3):128-32. PubMed ID: 2491186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prolonged antihypertensive effect of beta-adrenolytic treatment with Visken in patients with essential hypertension].
    Lukasik S; Halawa B; Surowiak M; Kasprzak J
    Pol Tyg Lek; 1977 Nov; 32(47):1837-9. PubMed ID: 341096
    [No Abstract]   [Full Text] [Related]  

  • 36. Pindolol (Visken) and angina pectoris: a double blind multicentre trial.
    Thorpe P
    N Z Med J; 1972 Sep; 76(484):171-3. PubMed ID: 4564998
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
    J Hum Hypertens; 1992 Jun; 6(3):181-4. PubMed ID: 1352827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cross-over trial with Peripress (prazosin) and Apresolin (hydralazin), both in combination with beta-blocker].
    Melkild A
    Tidsskr Nor Laegeforen; 1980 Jan; 100(3):148-49. PubMed ID: 6992338
    [No Abstract]   [Full Text] [Related]  

  • 39. Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.
    Frewin DB; Penhall RK; Leonello PP; Clapp RJ
    N Z Med J; 1980 Nov; 92(672):389-90. PubMed ID: 6937768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of pindolol (Visken) on plasma and blood volume in men with primary arterial hypertension].
    Wyrzykowski B; Suchecka-Rachoń K
    Pol Tyg Lek; 1985 Sep; 40(38):1083-6. PubMed ID: 3906604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.